Drug Approval | April 24, 2023
USFDA lifts clinical hold on Phase 3 investigational new drug application for MaaT013
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
